Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy

MLA

Karen A. Rossi, et al. “Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.” Journal of Medicinal Chemistry, vol. 65, no. 3, Sept. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0bf4f1ea39b0f4f590f90003f6f693cc&authtype=sso&custid=ns315887.

APA

Karen A. Rossi, Ruth R. Wexler, Steven Sheriff, Dawn Sun, Jeffrey M. Bozarth, Jianqing Li, Elizabeth A. Dierks, James R. Corte, Yiming Wu, Donald J. P. Pinto, Silvi A. Chacko, Michael Galella, Joanna J. Zheng, Joseph E. Myers, Dauh-Rurng Wu, Tianan Fang, Joseph M. Luettgen, Pancras C. Wong, Xiaoping Hou, … Theresa Ziemba. (2021). Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy. Journal of Medicinal Chemistry, 65(3).

Chicago

Karen A. Rossi, Ruth R. Wexler, Steven Sheriff, Dawn Sun, Jeffrey M. Bozarth, Jianqing Li, Elizabeth A. Dierks, et al. 2021. “Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.” Journal of Medicinal Chemistry 65 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0bf4f1ea39b0f4f590f90003f6f693cc&authtype=sso&custid=ns315887.